Elsevier

The American Journal of Cardiology

Volume 141, 15 February 2021, Pages 153-154
The American Journal of Cardiology

Systemic Fibrinolytic Therapy Versus Ultrasound-Assisted Catheter-Directed Thrombolysis for Acute İntermediate-High Risk Pulmonary Embolism

https://doi.org/10.1016/j.amjcard.2020.12.002Get rights and content

Section snippets

Disclosures

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

References (6)

  • M Sharifi et al.

    Moderate pulmonary embolism treated with thrombolysis (from the ‘MOPETT’ trial)

    Am J Cardiol

    (2013)
  • J Stępniewski et al.

    Hemodynamic effects of ultrasound-assisted, catheter-directed, very low-dose, short-time duration thrombolysis in acute intermediate-high risk pulmonary embolism (from the EKOS-PL Study)

    Am J Cardiol

    (2020)
  • A Güner et al.

    Clinical safety and efficacy of thrombolytic therapy with low-dose prolonged infusion of tissue type plasminogen activator in patients with intermediate-high risk pulmonary embolism

    Blood Coagul Fibrinolysis

    (2020)
There are more references available in the full text version of this article.

Cited by (0)

Funding: The author(s) received no financial support for the research, authorship, and/or publication of this article.

View full text